Uniting Global Biopharma Leaders to Enhance Translational Tools like EEG, Reinvent Patient Stratification, Explore Novel Endpoints & Drive Patient-Centered Innovations
Despite high‑profile Phase II/III setbacks, neuropsychiatric drug development is entering a renewed phase of momentum. From the Delix’s non‑hallucinogenic neuroplastogens and MapLight’s muscarinic push following a $250M IPO, to Compass Pathways advancing toward the first psychedelic approval, industry commitment to tackling the most persistent mental health challenges has never been stronger.
With hundreds of programs spanning depression, schizophrenia, psychosis, anxiety, sleep and SUDs, and surging investment across psychedelics, muscarinics, orexins, serotonergic agonists and novel modalities, confidence is returning. Learnings from 2025 failures are driving more resilient strategies, grounded in biology‑first hypotheses, smarter patient stratification, EEG and digital biomarkers, sleep and speech endpoints, and regulatory‑ready translational frameworks, to finally overcome placebo effects, heterogeneity, and late‑stage attrition.
Uniting 150+ senior leaders across discovery, preclinical, translational, clinical, regulatory and investment, with 35+ speakers from AbbVie, Gilgamesh, Otsuka, Neumora, Lundbeck, Boehringer Ingelheim, Bristol Myers Squibb, Monument Therapeutics, COMPASS Pathways, Karuna Therapeutics, Alto Neuroscience, Eli Lilly and more, the 9th Neuropsychiatric Drug Development Summit is the definitive forum accelerating the next era of precision psychiatry and patient‑centered mental health innovation.
The Neuropsychiatric Drug Development conference is an excellent opportunity to learn about cutting edge science and drug development in an intimate setting. It has consistently been an engaging and collaborative environment where we are able to interact with our peers who share the common goal of finding the best new therapies for patients.
Christopher Ocampo, Head of Psychiatry, Neuroscience Clinical Development, AbbVie
High quality presentations across preclinical, translational, and clinical development with both small biotech and big pharma represented. The size of the meeting made networking much easier than larger meetings.
Samuel Banister, Co‑Founder & CSO, Xylo Bio
For the challenges of neuropsychiatric drug development, this conference did an excellent job in selecting the topics for the various sessions. The short 2-day format was also well thought-out, and well-planned. Overall, it was an exhilarating 2-days, spent with folks facing similar challenges and discussing solutions and strategies to move forward to address the tremendous need for new approaches in mental health disorders.
Nurulain Zaveri, Founder & President, CSO, Astraea Therapeutics
Explore the Full Event Guide
- 35+ World Class Speakers with Cutting Edge Insights
- 10+ Hours of Face-to-Face Networking Opportunities
- 3 Days of Unmissable Data-Driven Content
- 2 Dedicated Tracks of Content Spanning Discovery to Access for the Whole Team
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Dive into 2 tracks, spanning discovery – clinical development and access, 3 preconference day workshops and 35+ expert speakers shaping the future of psychiatric R&D
Partner With Us
Showcase your solutions, connect with decision makers, and position your company as the go-to provider in neuropsychiatric and neurodevelopment research
Join Biopharma Experts
Network with pharma, biotech, diagnostics, academia, consortia, and regulatory voices driving real-world adoption